DBEU - ETF AI Analysis

Top Page

Xtrackers MSCI Europe Hedged Equity ETF (DBEU)

Rating:64Neutral

Price Target:―

DBEU’s rating suggests it is a solid, but not top-tier, way to invest in European stocks while hedging currency risk. Strong holdings like HSBC, AstraZeneca, Novartis, and ASML support the fund’s quality through robust financial performance, positive earnings outlooks, and generally reasonable valuations. However, some positions such as SAP and Shell face issues like bearish or weak technical trends, potential overvaluation, and growth challenges, and the fund’s concentration in European markets is a key risk if the region underperforms.

Positive Factors

Solid Recent Performance

The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.

Geographic Diversification Across Europe

Holdings spread across major European markets like the UK, France, Germany, Switzerland, and others help reduce the impact of weakness in any single country.

Balanced Sector Mix

Exposure to a range of sectors, including financials, industrials, health care, and technology, provides a more balanced risk profile than focusing on just one industry.

Negative Factors

Moderate Expense Ratio

The fund’s expense ratio is not especially low, meaning fees may be higher than some cheaper index ETFs and can slightly reduce long-term returns.

Mixed Performance Among Top Holdings

While some leading positions like ASML and Siemens have performed strongly, others such as SAP, Nestlé, and AstraZeneca have been weaker, creating uneven contribution to returns.

High Weight in Financials

A relatively large allocation to financial stocks increases the fund’s sensitivity to banking and interest-rate related risks in Europe.

DBEU vs. SPDR S&P 500 ETF (SPY)

AUM679.36M

RegionEurope

Expense Ratio0.45%

Beta0.60

IssuerXtrackers

Inception DateOct 01, 2013

Dividend Yield4.4%

Asset ClassEquity

Index TrackedMSCI Europe 100% Hedged to USD Net Variant

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume40,590

30 Day Avg. Volume58,669

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

54.60

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering398

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

DBEU Summary

DBEU is an ETF that follows the MSCI Europe U.S. Dollar Hedged Index, giving you broad exposure to large and mid-sized companies across many European countries while trying to reduce the impact of currency swings between the euro and the U.S. dollar. It holds well-known names like Nestlé and AstraZeneca, along with many banks, industrial firms, and health care companies. Someone might invest in DBEU to diversify beyond the U.S. and tap into Europe’s long-term growth while limiting currency risk. A key risk is that European stock prices can still go up and down with the overall market and regional economies.

How much will it cost me?The Xtrackers MSCI Europe Hedged Equity ETF (DBEU) has an expense ratio of 0.45%, meaning you’ll pay $4.50 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it includes a currency hedging strategy to reduce the impact of exchange rate fluctuations.

What would affect this ETF?The DBEU ETF could benefit from positive economic growth in Europe, particularly in sectors like financials and industrials, which make up a significant portion of its holdings. Additionally, its currency hedging strategy provides protection against euro-to-dollar fluctuations, which can stabilize returns for U.S. investors. However, potential risks include economic slowdowns in Europe, regulatory changes affecting key industries, or geopolitical tensions that could impact the performance of its top holdings like ASML and Nestlé.

DBEU Top 10 Holdings

DBEU’s story right now is being written by a handful of European heavyweights. ASML is the clear engine, with its rising share price giving the fund a strong tech tailwind, while Siemens and HSBC are also pulling their weight with steady gains from industrials and financials. On the defensive side, big pharma names like Roche and Novartis are quietly supporting performance with solid, if unspectacular, advances. Offsetting that strength, Nestlé and SAP have been losing steam, acting as mild drags. Overall, it’s a diversified, developed-Europe mix rather than a single-sector bet.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	3.95%	$26.77M	€464.34B	67.81%	76 Outperform
ROG	Roche Holding AG	2.27%	$15.38M	CHF279.83B	41.58%	73 Outperform
HSBA	HSBC Holdings	2.15%	$14.60M	£220.77B	51.99%	80 Outperform
AZN	AstraZeneca	2.06%	$13.94M	£210.86B	19.89%	80 Outperform
NOVN	Novartis AG	2.03%	$13.73M	CHF218.15B	19.92%	80 Outperform
NESN	Nestlé SA	1.77%	$11.96M	CHF185.72B	12.00%	71 Outperform
SIE	Siemens	1.66%	$11.24M	€199.98B	24.44%	74 Outperform
SHEL	Shell (UK)	1.59%	$10.77M	£158.23B	4.31%	73 Outperform
SAP	SAP SE	1.47%	$9.94M	€194.20B	-37.58%	66 Neutral
	―	1.36%	$9.24M	―	―	―

DBEU Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

48.04

Positive

100DMA

46.98

Positive

200DMA

45.22

Positive

Market Momentum

MACD

0.39

Positive

RSI

60.12

Neutral

STOCH

58.38

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DBEU, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 49.40, equal to the 50-day MA of 48.04, and equal to the 200-day MA of 45.22, indicating a bullish trend. The MACD of 0.39 indicates Positive momentum. The RSI at 60.12 is Neutral, neither overbought nor oversold. The STOCH value of 58.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBEU.

DBEU Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
DBEU	―	―	$679.36M	0.45%	―
VGK	―	―	$31.27B	0.06%	―
SPEU	―	―	$767.55M	0.07%	―
FEUZ	―	―	$123.71M	0.80%	―
FLEE	―	―	$122.38M	0.09%	―
GSEU	―	―	$121.28M	0.25%	―

Performance Comparison

DBEU

Xtrackers MSCI Europe Hedged Equity ETF

49.61

8.05

19.37%

VGK

Vanguard FTSE Europe ETF

―

SPEU

SPDR Portfolio Europe ETF

―

FEUZ

First Trust Eurozone AlphaDEX ETF

―

FLEE

Franklin FTSE Europe ETF

―

GSEU

Goldman Sachs ActiveBeta Europe Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents